XNCR
- Xencor, Inc.
()
Overview
Company Summary
Xencor, Inc. (XNCR) is a biopharmaceutical company that focuses on discovering and developing innovative antibody-based therapeutics. The company utilizes its proprietary XmAb antibody engineering platform to create and optimize monoclonal antibodies, which are a type of protein that can specifically target and bind to disease-causing molecules in the body.
One of the core activities of Xencor is the development of its pipeline of drug candidates, which are designed to treat a variety of diseases, including cancer, autoimmune disorders, and allergic conditions. These drug candidates are developed by modifying the antibodies at specific regions to enhance their therapeutic properties, such as increased potency or longer half-life.
Moreover, Xencor engages in strategic collaborations with pharmaceutical and biotechnology companies to leverage its antibody engineering technology. Through these partnerships, Xencor's XmAb platform is employed to improve the efficacy and safety of therapeutic antibodies developed by its collaborators, thereby enhancing the chances of successful clinical outcomes.
In summary, Xencor, Inc. is a biopharmaceutical company that specializes in the discovery and development of antibody-based therapeutics using its proprietary antibody engineering platform. The company aims to create innovative drugs that can effectively treat various diseases and disorders, either through its internal pipeline or in collaboration with other industry partners.